Meeting NewsVideo

VIDEO: Targeted agents, immunotherapies fill unmet needs for hard-to-treat cancers

CHICAGO — Aron Knickerbocker, MBA, CEO of Five Prime Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about advances in the company’s oncology program.

One study presented at ASCO focused on use of cabiralizumab (FPA008, Five Prime Therapeutics) — an antibody that inhibits colony stimulating factor-1 receptor — in combination with the PD-1 immune checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) for heavily pretreated patients with pancreatic cancer.

“Nearly all of the patients in this study were tumor mutation burden low, and those are not the type of patients who are historically very sensitive to PD-1 inhibition, so that is very interesting,” Knickerbocker told HemOnc Today.

Knickerbocker also spoke about bemarituzumab (FPA144, Five Prime Therapeutics) — an antibody that targets FGF receptor 2, which is overexpressed in approximately 10% of gastric and gastroesophageal cancers — as well as what he described as other “first-in-class immuno-oncology agents” in the company’s pipeline.

“A lot is going over the next 6 to 12 months at Five Prime, and we should end the year with five products in development between us and our partners,” Knickerbocker told HemOnc Today.

CHICAGO — Aron Knickerbocker, MBA, CEO of Five Prime Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about advances in the company’s oncology program.

One study presented at ASCO focused on use of cabiralizumab (FPA008, Five Prime Therapeutics) — an antibody that inhibits colony stimulating factor-1 receptor — in combination with the PD-1 immune checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) for heavily pretreated patients with pancreatic cancer.

“Nearly all of the patients in this study were tumor mutation burden low, and those are not the type of patients who are historically very sensitive to PD-1 inhibition, so that is very interesting,” Knickerbocker told HemOnc Today.

Knickerbocker also spoke about bemarituzumab (FPA144, Five Prime Therapeutics) — an antibody that targets FGF receptor 2, which is overexpressed in approximately 10% of gastric and gastroesophageal cancers — as well as what he described as other “first-in-class immuno-oncology agents” in the company’s pipeline.

“A lot is going over the next 6 to 12 months at Five Prime, and we should end the year with five products in development between us and our partners,” Knickerbocker told HemOnc Today.

    See more from ASCO Annual Meeting